These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37076395)

  • 1. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
    Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
    Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
    Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
    Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
    Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
    ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
    Nakagawa K; Nadal E; Garon EB; Nishio M; Seto T; Yamamoto N; Park K; Shih JY; Paz-Ares L; Frimodt-Moller B; Zimmermann AH; Wijayawardana S; Visseren-Grul C; Reck M
    Clin Cancer Res; 2021 Oct; 27(19):5258-5271. PubMed ID: 34301751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
    Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
    Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
    Chiu CH; Lin MC; Wei YF; Chang GC; Su WC; Hsia TC; Su J; Wang AK; Jen MH; Puri T; Shih JY
    Target Oncol; 2023 Jul; 18(4):505-515. PubMed ID: 37329423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
    Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
    Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
    Nakagawa K; Garon EB; Gao L; Callies S; Zimmermann A; Walgren R; Visseren-Grul C; Reck M
    Cancer Chemother Pharmacol; 2022 Aug; 90(2):137-148. PubMed ID: 35841410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RELAY, Erlotinib Plus Ramucirumab in Untreated,
    Nishino K; Shih JY; Nakagawa K; Reck M; Garon EB; Carlsen M; Matsui T; Visseren-Grul C; Nadal E
    JTO Clin Res Rep; 2024 Feb; 5(2):100624. PubMed ID: 38304857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic
    Nishio K; Seto T; Nishio M; Reck M; Garon EB; Sakai K; Goto K; Kato T; Nakanishi Y; Takahashi T; Yamamoto N; Kiura K; Ohe Y; Tamura T; Visseren-Grul C; Frimodt-Moller B; Hozak RR; Wijayawardana SR; Zimmermann A; Homma G; Enatsu S; Nakagawa K
    JTO Clin Res Rep; 2021 Jun; 2(6):100171. PubMed ID: 34590023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with
    Nishio K; Sakai K; Nishio M; Seto T; Visseren-Grul C; Carlsen M; Matsui T; Enatsu S; Nakagawa K
    Transl Lung Cancer Res; 2023 Aug; 12(8):1702-1716. PubMed ID: 37691865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated
    Yoh K; Atagi S; Reck M; Garon EB; Ponce Aix S; Moro-Sibilot D; Winfree KB; Frimodt-Moller B; Zimmermann A; Visseren-Grul C; Nakagawa K;
    Curr Med Res Opin; 2020 Oct; 36(10):1667-1675. PubMed ID: 32780643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
    Landre T; Des Guetz G; Chouahnia K; Duchemann B; Assié JB; Chouaid C
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3333-3339. PubMed ID: 32632581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
    Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort.
    Machado-Rugolo J; Baldavira CM; Prieto TG; Olivieri EHR; Fabro AT; Rainho CA; Castelli EC; Ribolla PEM; Ab'Saber AM; Takagaki T; Nagai MA; Capelozzi VL
    Braz J Med Biol Res; 2023; 56():e12488. PubMed ID: 37042869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
    Haratake N; Hayashi H; Shimokawa M; Nakano Y; Azuma K; Oki M; Ota K; Yoshioka H; Sakamoto T; Yamamoto N; Nakagawa K; Seto T
    Clin Lung Cancer; 2022 May; 23(3):e257-e263. PubMed ID: 34887192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.